Both are astonishingly capable, but subscription choices, coding environments, and hidden ecosystem advantages could make one ...
Kyoto Fusioneering and Oak Ridge National Laboratory are tackling the fusion industry's biggest fuel challenge with the UNITY-3 project.
The Air Force has awarded three companies a set of task orders with a combined $1.9 billion ceiling over up to five years for technical and management advisory support services. Aventis won two task ...
What is the 3:3 Program with Columbia? Colorado College is proud to sponsor a special program with Columbia Law School in New York. The 3+3 program allows qualified CC undergraduates admission to ...
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already includes 17 global phase 3 trials. But there’s one important missing piece. The New ...
Alkermes initiated three pivotal 12-week, randomized, double-blind trials comparing alixorexton with placebo in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Mechanistically, ...
Facebook Twitter WhatsApp SMS Email Print Copy article link Save Facebook Twitter WhatsApp SMS Email Print Copy article link Save Purchase Article Reprint Dubuque's Loras College will partner with a ...
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...
Scott McLaughlin qualified on pole for last year’s race at St. Petersburg and finished fourth. On his return to the Floridian street course, the Team Penske driver captured pole once more and finished ...
– Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m 2 or greater – – KaiNETIC program includes three Phase 3 clinical ...
Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. “Due ...
Vorolanib in DURAVYU inhibits IL-6-mediated inflammation by blocking JAK receptors, showing sustained improvements in the phase 2 VERONA trial. The phase 3 program includes two non-inferiority trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results